Welcome to our dedicated page for OKYO PHARMA SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain, dry eye disease, and ocular inflammatory conditions. As a foreign private issuer, OKYO submits Form 6-K reports under the Securities Exchange Act of 1934, which furnish key company announcements to investors.
Recent 6-K filings referenced in public disclosures include exhibits covering share acquisitions by Panetta Partners Limited, an entity in which OKYO’s Executive Chairman has a beneficial interest, with details on the number of ordinary shares acquired on NASDAQ and updated total holdings. Other 6-Ks furnish announcements about clinical development milestones, such as the registration pathway and planned 100-patient multi-center trial of urcosimod in neuropathic corneal pain, as well as notices of management presentations at industry meetings like the Ophthalmology Innovation Summit and BIO-Europe.
Through Stock Titan, users can access these filings as they are made available from EDGAR and review the attached exhibits that describe OKYO’s clinical progress, regulatory plans, and significant ownership changes. AI-powered summaries help explain the contents of each filing in plain language, highlighting why a particular 6-K may matter for understanding OKYO’s development of urcosimod and its broader ophthalmology strategy.
For investors analyzing OKYO, this filings page offers a structured way to follow its ongoing disclosure record, from clinical trial updates and registration pathway discussions to insider-related share purchases reported via Form 6-K. The combination of real-time access and AI-generated insights can support more efficient review of OKYO’s regulatory communications.
OKYO Pharma Limited is conducting a primary offering of ordinary shares on The Nasdaq Capital Market under its F-3 shelf registration. The shares will be sold through an underwritten public offering led by Piper Sandler, with an additional 30-day option for underwriters to buy more shares.
OKYO expects to use the net proceeds for clinical development of its product candidates, general corporate purposes and working capital. As an emerging growth company, it follows reduced reporting requirements and warns investors about high investment risk, potential dilution from this and future equity issuances, and the possibility of Nasdaq delisting if listing standards are not maintained.
OKYO Pharma Limited has transitioned its at-the-market equity offering facility to Leerink Partners LLC, replacing its prior arrangement with B. Riley Securities. Leerink will act as exclusive sales agent, able to sell OKYO common shares into the market from time to time at prevailing prices.
The ATM program is intended to give OKYO ongoing access to equity capital, at the Company’s discretion and subject to market conditions, with Leerink earning a commission equal to 3.0% of gross proceeds from any shares sold. Management highlights this as enhancing financial flexibility to fund clinical development, including the lead candidate urcosimod for neuropathic corneal pain.
OKYO Pharma Ltd. has established an at the market offering program allowing it to sell up to
The shares will be issued under OKYO’s effective Form F-3 shelf registration and a related prospectus supplement. Leerink Partners will receive a
OKYO Pharma Limited is establishing an at-the-market program to sell up to $50 million of ordinary shares through Leerink Partners on Nasdaq under the symbol OKYO.
Leerink Partners will act as sales agent or principal and earn a 3% commission on gross proceeds. Based on an illustrative price of $1.99, the company shows a scenario where shares outstanding could rise from 40,555,197 to up to 65,680,825, highlighting potential dilution for new and existing holders.
OKYO plans to use any net proceeds for clinical development, general corporate purposes and working capital, with a primary focus on advancing its lead drug candidate urcosimod for neuropathic corneal pain, an indication with no FDA‑approved therapies. Urcosimod has Fast Track designation and encouraging Phase 2a and dry eye disease data, but the company notes significant risks, including ongoing losses, future financing needs, and the possibility of Nasdaq delisting.
OKYO Pharma has appointed Flavio Mantelli, MD, PhD as Chief Medical Officer, adding a seasoned ophthalmology leader to its executive team. He previously led the clinical development, FDA approval and global strategy of Oxervate, an orphan corneal therapy that achieved blockbuster status with sales topping $1 billion in 2024.
At OKYO, Dr. Mantelli will oversee clinical and regulatory strategy, focusing on advancing urcosimod for neuropathic corneal pain and additional orphan indications. Urcosimod has FDA Fast Track designation, the first IND for NCP, compassionate use authorization, positive Phase 2 pain‑reduction data in NCP and earlier efficacy data in dry eye disease. OKYO plans a ~150‑subject Phase 2b/3 multiple‑dose NCP study in the first half of this year.
OKYO Pharma Limited has filed a shelf registration statement on Form F-3 to offer up to
OKYO is a clinical-stage biopharmaceutical company developing urcosimod for neuropathic corneal pain and dry eye disease, with FDA Fast Track status for neuropathic corneal pain. The company highlights substantial ongoing losses, limited cash resources, and a going-concern warning, underscoring its dependence on future financings and successful trial outcomes.
OKYO Pharma reported interim results for the six months ended 30 September 2025, highlighting progress on its lead drug urcosimod for neuropathic corneal pain (NCP). The company secured FDA Fast Track Designation for urcosimod in NCP and reported strong Phase 2 proof-of-concept data in 18 patients, with 75% of per-protocol patients achieving more than 80% pain reduction on the Visual Analogue Scale after 12 weeks.
OKYO also strengthened its leadership by appointing Robert J. Dempsey as Chief Executive Officer and transitioning former CEO Gary S. Jacob to Chief Development Officer. Following a successful FDA Type C meeting, the agency confirmed alignment on the proposed 150-patient Phase 2b/3 trial design, including a primary endpoint of VAS pain reduction at Week 12.
Financially, total assets were $4.6 million as of 31 March 2025, with cash on hand of $4.2 million, up from $1.6 million. The company recorded a total comprehensive loss of $3.0 million, slightly improved from a $3.2 million loss for the comparable prior-year period.
OKYO Pharma Limited filed a Form 6-K to share that an abstract on its lead drug candidate urcosimod (formerly OK-101) has been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The paper will present proof-of-concept Phase 2 efficacy and safety results in neuropathic corneal pain during the Ocular Surface Disease II session on April 11, 2026, in Washington, DC.
The company highlights positive efficacy signals from the completed Phase 2 trial, including meaningful pain reduction and encouraging corneal nerve health trends, and describes urcosimod as a potential first-in-class therapy for neuropathic corneal pain, which currently has no FDA-approved treatments. OKYO reiterates prior FDA fast track designation and the first IND for NCP, and states it plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod in the first half of 2026.
OKYO Pharma reports that the FDA held a successful Type C meeting with the company on the Phase 2b/3 clinical trial of urcosimod for neuropathic corneal pain (NCP). The FDA confirmed the planned trial design, including the primary endpoint, sample size, and overall development approach.
Urcosimod already has the first IND for NCP and fast track designation, and OKYO recently completed a positive Phase 2 NCP trial and an earlier 240-patient Phase 2 dry eye disease study with statistically significant results. The company plans to start a 120-patient Phase 2b/3 multiple-dose study for NCP in the first half of the year, aiming to address a condition with no FDA-approved treatments.